Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 29% primary Improvement Relative Risk Ventilation 28% primary Clinical status 25% Recovery time 25% Hospitalization time 29% c19early.org/j Ameri et al. Melatonin for COVID-19 RCT ICU PATIENTS Favors melatonin Favors control
Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial
Ameri et al., Inflammopharmacology, doi:10.1007/s10787-022-01096-7
19 Nov 2022    Source   PDF   Share   Tweet
RCT 226 ICU patients in Iran, showing lower mortality with melatonin treatment.
risk of death, 28.8% lower, RR 0.71, p < 0.001, treatment 73 of 109 (67.0%), control 110 of 117 (94.0%), NNT 3.7, primary outcome.
risk of mechanical ventilation, 27.6% lower, RR 0.72, p = 0.003, treatment 56 of 109 (51.4%), control 83 of 117 (70.9%), NNT 5.1, primary outcome.
clinical status, 25.0% lower, RR 0.75, p = 0.001, treatment 109, control 117, day 14.
recovery time, 25.0% lower, relative time 0.75, p = 0.04, treatment 109, control 117.
hospitalization time, 28.6% lower, relative time 0.71, p = 0.03, treatment 109, control 117.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ameri et al., 19 Nov 2022, Randomized Controlled Trial, Iran, peer-reviewed, 9 authors, study period 1 March, 2021 - 30 November, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit